WallStSmart

ChipMOS Technologies Inc (IMOS)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ChipMOS Technologies Inc generates 9144% more annual revenue ($23.93B vs $258.90M). IMOS leads profitability with a 2.1% profit margin vs -15.5%. IMOS earns a higher WallStSmart Score of 52/100 (C-).

IMOS

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 4.5Value: 3.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.99

ZEPP

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for IMOS.

ZEPPUndervalued (+48.9%)

Margin of Safety

+48.9%

Fair Value

$46.96

Current Price

$18.01

$28.95 discount

UndervaluedFair: $46.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IMOS3 strengths · Avg: 8.7/10
EPS GrowthGrowth
126.8%10/10

Earnings expanding 126.8% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
20.8%8/10

Revenue surging 20.8% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

IMOS4 concerns · Avg: 3.5/10
PEG RatioValuation
2.134/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Market CapQuality
$1.91B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.0%3/10

ROE of 2.0% — below average capital efficiency

ZEPP4 concerns · Avg: 2.3/10
Market CapQuality
$270.28M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Free Cash FlowQuality
$-26.48M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : IMOS

The strongest argument for IMOS centers on EPS Growth, Price/Book, Revenue Growth. Revenue growth of 20.8% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : IMOS

The primary concerns for IMOS are PEG Ratio, Altman Z-Score, Market Cap. A P/E of 111.8x leaves little room for execution misses. Thin 2.1% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

IMOS profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

IMOS generates stronger free cash flow (973M), providing more financial flexibility.

Bottom Line

IMOS scores higher overall (52/100 vs 38/100) and 20.8% revenue growth. ZEPP offers better value entry with a 48.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ChipMOS Technologies Inc

TECHNOLOGY · SEMICONDUCTORS · USA

ChipMOS TECHNOLOGIES INC. The company is headquartered in Hsinchu, Taiwan.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?